ClinicalTrials.gg

Program

Hizentra

Also written as “IgPro20”, “Human Normal Immunoglobulin for Subcutaneous Administration” and “Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)”.

Its studies are mostly in Primary Immunodeficiency Diseases · Hematologic Neoplasms · Postural Orthostatic Tachycardia Syndrome · Scleroderma, Diffuse · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, led by CSL.

Furthest: phase 4, since Jan 23, 20179 company-led studies, 1 open or runningNext primary completion: Sep 27, 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSL91 open or runningphase 4since Jan 23, 2017Dec 22, 2006Sep 27, 2029phase 3 · NCT07648264

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 22, 2006First study: phase 3 study in Primary Immunodeficiency DiseasesFirst studyNCT00419341 · 49 enrolled · United States
  2. Oct 11, 2007Phase 3 study in Common Variable ImmunodeficiencyNCT00542997 · 51 enrolled · France, Germany, Italy and more
  3. Jul 21, 2008Phase 3 study in Primary Immunodeficiency DiseasesNCT00719680 · 21 enrolled · United States
  4. Sep 11, 2008Phase 3 study in Primary Immunodeficiency DiseasesNCT00751621 · 40 enrolled · France, Germany, Poland and more
  5. Jan 3, 2014Phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT02027701 · 82 enrolled · United States, Australia, Canada and more
  6. Jan 23, 2017Phase 4 study in Primary Immunodeficiency DiseasesNCT03033745 · 49 enrolled · United States, Canada
  7. Oct 21, 2019Phase 2 study in Scleroderma, DiffuseNCT04137224 · 27 enrolled · Australia, Germany, Italy and more
  8. Jul 26, 2024Phase 3 study in Post-COVID Postural Orthostatic Tachycardia SyndromeNCT06524739 · 16 enrolled · United States, Canada
  9. Jun 10, 2026Phase 3 study in Hematologic NeoplasmsNCT07648264 · 63 planned · United States, Belgium, Canada and more
  10. Oct 14, 2026Primary completion moved from 2029-03-13 to 2029-09-27Date moved laterphase 3 · +7 months · NCT07648264

Ahead

  1. Sep 27, 2029Primary completion: phase 3 study in Hematologic NeoplasmsNCT07648264

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07648264Hematologic Neoplasms · United States, Belgium, Canada and more3RecruitingSep 27, 202963
NCT06524739Post-COVID Postural Orthostatic Tachycardia Syndrome · United States, Canada3TerminatedJun 20, 202516
NCT04137224Scleroderma, Diffuse · Australia, Germany, Italy and more2CompletedMay 17, 202227
NCT03033745Primary Immunodeficiency Diseases · United States, Canada4CompletedDec 14, 201849
NCT02027701Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Australia, Canada and more3CompletedJul 10, 201782
NCT00751621Primary Immunodeficiency Diseases · France, Germany, Poland and more3CompletedDec 201140
NCT00719680Primary Immunodeficiency Diseases · United States3CompletedJun 201021
NCT00542997Common Variable Immunodeficiency · France, Germany, Italy and more3CompletedAug 200951
NCT00419341Primary Immunodeficiency Diseases · United States3CompletedOct 200849

How it is read

Names in the registry

  • “IgPro20”, 7 entries
  • “Human Normal Immunoglobulin for Subcutaneous Administration”, 1 entry
  • “Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.